Search

Your search keyword '"Nakamura, Ryotaro"' showing total 729 results

Search Constraints

Start Over You searched for: Author "Nakamura, Ryotaro" Remove constraint Author: "Nakamura, Ryotaro" Language english Remove constraint Language: english
729 results on '"Nakamura, Ryotaro"'

Search Results

3. Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation

4. Yttrium-90 anti-CD25 BEAM conditioning for autologous hematopoietic cell transplantation in Peripheral T-cell lymphoma

5. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD

6. Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study

7. The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD

8. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD

11. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis

12. A Day 14 Endpoint for Acute GVHD Clinical Trials

13. Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients

15. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease

16. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma

17. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD

18. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

20. Association of pre-transplant vancomycin resistant enterococcus colonization status on long-term outcomes of allogeneic-hematopoietic cell transplantation

21. Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab

22. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study

23. A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract

24. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the American Society for Transplantation and Cellular Therapy Committee on Practice Guidelines

26. Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation

27. Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy

30. Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages

31. Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL

32. A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD

36. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study

37. Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.

38. SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.

39. Impact of Antifungal Prophylaxis Continuation or Discontinuation After Allogeneic Hematopoietic Cell Transplant on the Incidence of Invasive Mold Infection.

40. Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome‐positive acute lymphoblastic leukemia.

41. Challenges with sirolimus experimental data to inform QSP model of post‐transplantation cyclophosphamide regimens.

43. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide

45. Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation

47. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

48. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors

49. Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis

50. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin

Catalog

Books, media, physical & digital resources